| Literature DB >> 34781267 |
Andrew D Zelenetz1, Leo I Gordon2, Julie E Chang3, Beth Christian4, Jeremy S Abramson5, Ranjana H Advani6, Nancy L Bartlett7, L Elizabeth Budde8, Paolo F Caimi9, Sven De Vos10, Bhagirathbhai Dholaria11, Bita Fakhri12, Luis E Fayad13, Martha J Glenn14, Thomas M Habermann15, Francisco Hernandez-Ilizaliturri16, Eric Hsi9, Boyu Hu14, Mark S Kaminski17, Christopher R Kelsey18, Nadia Khan19, Susan Krivacic20, Ann S LaCasce21, Megan Lim22, Mayur Narkhede23, Rachel Rabinovitch24, Praveen Ramakrishnan25, Erin Reid26, Kenneth B Roberts27, Hayder Saeed28, Stephen D Smith29, Jakub Svoboda22, Lode J Swinnen30, Joseph Tuscano31, Julie M Vose32, Mary A Dwyer33, Hema Sundar33.
Abstract
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34781267 DOI： 10.6004/jnccn.2021.0054
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908